top of page

The Biden administration doubles the government's order of the new COVID-19 pill

Writer's picture: Capitol TimesCapitol Times



Pfizer's Paxlovid, an oral antiviral treatment, will be doubled in federal purchases by President Biden on Tuesday.

A total of 20 million therapeutic courses of the new pill will be purchased from Pfizer in the U.S. under this addition.


Paxlovid was recently approved for emergency use by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19 in patients over 12 years old.


Biden said in a speech on Jan. 4 that the pills would significantly reduce hospitalizations and deaths linked to COVID-19. He added, “They offer the potential to dramatically change the course of COVID-19.”


Pfizer announced in an announcement that 10 million people will receive the new treatment by the end of June, and the remaining 10 million will follow by the end of September.


“I’m pleased to say that on Christmas Eve, we shipped out the first batch of these pills that we purchased and received, and more will be shipped this week,” Biden said.


FDA approved Pfizer-BioNTech's COVID-19 vaccine in August, and it is the only vaccine marketed by Pfizer-BioNTech with FDA approval.


Over a million new COVID-19 cases were reported in the United States on Monday, but this could be partly due to a delay in reporting cases over the holiday weekend.


5 Jan 2022

Comments


Contact us

Letter to Editor-In-Chief
Editor@capitoltimesmedia.com

For Advertising in
Capitol Times Magazine:

ads@capitoltimesmedia.com

Capitol Times magazine Issue 5
Capitol times magazine 9
Capitol times magazine 10

Join our mailing list

FOLLOW US

  • X
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube

Disclaimer:

The views and opinions expressed in the articles or Interviews published in this magazine are solely those of the respective authors and do not necessarily reflect the official policy or position of the Capitol Times magazine or Capitol Times Media , its editors, or its staff. The authors are solely responsible for the content of their articles. The magazine strives to provide a platform for diverse voices and opinions, and we value the principle of free expression. The magazine assumes no responsibility or liability for any errors or omissions in the content of the articles. In no event shall the Capitol Times magazine or Capitol Times Media be liable for any special, direct, indirect, or incidental damages. Furthermore, the inclusion of advertisements or sponsored content in Capitol Times magazine does not constitute an endorsement or guarantee of the products, services, or views promoted by the advertisers. Readers are encouraged to conduct their own research and exercise caution when making decisions based on advertisements or sponsored content featured in this publication.

Thank you for reading and engaging with our publication. Your feedback is valuable to us as we continue to provide a platform for thought-provoking content and diverse perspectives.

© 2024 by Capitol Times Media LLC - Privacy Policy

bottom of page